BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., August 12, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on August 3, 2020, the compensation committee of BridgeBio’s board of directors granted twenty-two employees options to purchase an aggregate of 30,443 shares of the Company’s common stock with a […]

BridgeBio Pharma, Inc. Reports Second Quarter 2020 Financial Results and Business Update

– Initiated four clinical trials, progressed its additional 11 ongoing clinical trials and submitted three INDs to FDA since the beginning of 2020 -Strategic collaboration with Perceptive Advisors-founded company LianBio expands BridgeBio’s global reach into China -Ended quarter with $840.9 million in cash, cash equivalents and marketable securities SAN FRANCISCO, AUGUST 11, 2020 – BridgeBio […]

BridgeBio Pharma Expands Reach Into China and Other Major Asian Markets Through Strategic Collaboration With Perceptive Advisors-Founded Company, LianBio

中文版请参见此链接 $26.5 million total near-term payments to BridgeBio, plus participation in long-term value creation of up to $505 million in milestone payments, tiered double-digit royalty payments and an equity interest in LianBio. BridgeBio CEO and founder Neil Kumar, Ph.D., has been appointed to LianBio’s board of directors. PALO ALTO, CA – August 11, 2020 – […]